63166-73-4

Usage

Uses

Used in Pharmaceutical Industry:
Phyllanthoside is used as a therapeutic agent for its hepatoprotective properties, aiding in the treatment of liver disorders and potentially offering a solution for chronic hepatitis B due to its antiviral activity against the hepatitis B virus.
Used in Nutraceutical Industry:
Phyllanthoside is utilized as a dietary supplement for its antioxidant and anti-inflammatory properties, contributing to overall health and well-being by supporting the immune system and reducing inflammation.
Used in Urological Applications:
Phyllanthoside is employed as a treatment for urinary tract infections and kidney stones, leveraging its potential to alleviate symptoms and improve urological health.
Used in Antiviral Therapies:
Phyllanthoside is used as an antiviral agent specifically targeting the hepatitis B virus, offering a potential treatment for individuals suffering from chronic hepatitis B and contributing to antiviral drug development.

Upstream product

• 18439-45-7 3-O-Benzyl-6-desoxy-1,2-O-isopropyliden-α-D-gluco-hexofuranose 
• 106711-52-8 Acetic acid (2R,3R,4S,5R,6R)-5-acetoxy-4-benzyloxy-2-bromo-6-methyl-tetrahydro-pyran-3-yl ester 
• 106711-54-0 C₂₀H₂₆O₆ 
• 106711-56-2 Acetic acid (2R,3R,4R,5R,6R)-6-allyloxy-4-benzyloxy-5-hydroxy-2-methyl-tetrahydro-pyran-3-yl ester 
• 106711-55-1 Acetic acid (2R,3R,4R,5R,6S)-6-allyloxy-4-benzyloxy-5-hydroxy-2-methyl-tetrahydro-pyran-3-yl ester 
• 106711-51-7 acetyl 2,4-O-diacetyl-3-O-benzyl-6-deoxy-α/β-D-glucopyranoside 
• 102-92-1 Cinnamoyl chloride 
• 106711-64-2 Formic acid (2R,3R,4R,5S,6R)-4-hydroxy-3-((2S,3R,4S,5S,6R)-4-hydroxy-6-methyl-3,5-bis-triethylsilanyloxy-tetrahydro-pyran-2-yloxy)-6-methyl-5-triethylsilanyloxy-tetrahydro-pyran-2-yl ester 
• 134311-85-6 Formic acid (2S,3R,4R,5S,6R)-4-hydroxy-3-((2S,3R,4S,5S,6R)-4-hydroxy-6-methyl-3,5-bis-triethylsilanyloxy-tetrahydro-pyran-2-yloxy)-6-methyl-5-triethylsilanyloxy-tetrahydro-pyran-2-yl ester 
• 106711-61-9 (2S,3R,4S,5R,6R)-4-Benzyloxy-2-{(2S,3R,4S,5R,6R)-4-benzyloxy-5-hydroxy-6-methyl-2-[((E)-propenyl)oxy]-tetrahydro-pyran-3-yloxy}-6-methyl-tetrahydro-pyran-3,5-diol 
• 106711-61-9 (2S,3R,4S,5R,6R)-4-Benzyloxy-2-{(2R,3R,4S,5R,6R)-4-benzyloxy-5-hydroxy-6-methyl-2-[((E)-propenyl)oxy]-tetrahydro-pyran-3-yloxy}-6-methyl-tetrahydro-pyran-3,5-diol 
• 106711-68-6 C₄₉H₈₆O₁₆Si₃ 
• 106711-69-7 C₄₉H₈₈O₁₆Si₃ 
• 106711-62-0 C₄₇H₈₀O₉Si₃ 

Downstream Products

• 62955-96-8 C₄₆H₅₈O₂₀ 
• 62948-37-2 phyllanthocin 
• 16741-34-7 phyllanthose 
• 81558-18-1 (+)-phyllanthostatin 2 
• 82209-93-6 (+)-phyllanthostatin 1 

Relevant academic research and scientific papers

Phyllanthoside-Phyllanthostatin Synthetic Studies. 8. Total Synthesis of (+)-Phyllanthoside. Development of the Mitsunobu Glycosyl Ester Protocol

The first total syntheses of the antineoplastic glycoside (+)-phyllanthoside (1) and the parent disaccharide (-)-phyllanthose (5) have been achieved. Stereoselective Koenigs-Knorr coupling of two 6-deoxyglucose derivatives, bromide 54 and alcohol 55, generated the uncommon 1′ → 2β glycosidic linkage of (-)-phyllanthose. A stereochemically convergent Mitsunobu reaction of protected disaccharide 87 with aglycon carboxylic acid 80, prepared via asymmetric synthesis, then led to 1 of high enantiomeric purity. The Mitsunobu procedure comprises an efficient general method for stereospecific assembly of β-glycosyl esters.